Physician profile

William Smith

Cardiovascular Disease · Ruston, LA

NPI 1992776231

$7,685.07

in general payments reported to CMS, 2019-2025

44 companies · $1,523 in 2025

The $1,523 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,333.44

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $984.60 2019-2025 Lifevest
Astrazeneca Pharmaceuticals LP $785.78 2020-2025 Farxiga, Lokelma
Sanofi-Aventis U.S. LLC $538.14 2019-2023
Janssen Pharmaceuticals, INC $524.73 2019-2022
Merck Sharp & Dohme LLC $479.09 2021-2025 Verquvo
Boehringer Ingelheim Pharmaceuticals, INC. $456.78 2021-2025 Jardiance
E.R. Squibb & Sons, L.L.C. $450.31 2019-2025 Eliquis, Camzyos
Novartis Pharmaceuticals Corporation $437.89 2019-2024
Amgen INC. $359.62 2019-2024 Repatha
Pfizer INC. $342.98 2019-2025
Actelion Pharmaceuticals US, INC. $230.15 2019-2025 Opsumit
Bayer Healthcare Pharmaceuticals INC. $227.98 2021-2025
Artivion, INC. $211.13 2024-2025 Amds-Ascyrus Medical, On-X Aortic Heart Valve With Conform-X Sewing Ring and Extended Holder
Abiomed $193.19 2021-2025 Impella
Medtronic, INC. $172.88 2025 Corevalve Evolut R, Aurora Ev-Icd Mri Surescan
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Kowa Pharmaceuticals America, INC. $140.96 2019-2021
Regeneron Healthcare Solutions, INC. $124.18 2019-2025 Evkeeza
Amarin Pharma, INC. $105.02 2021-2022
Irhythm Technologies, INC. $102.63 2019-2024 Zio Xt Patch, Zio Monitor
Ucb, INC. $97.87 2025 Bimzelx
Penumbra, INC. $89.53 2021
Davol INC. $85.87 2024 Progel Applicator Spray Tips
Kestra Medical Technology Services, INC. $65.40 2025 Assure Wcd
Alnylam Pharmaceuticals INC. $57.53 2019-2025 Amvuttra
Silk Road Medical, INC. $56.27 2021-2024 Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter
Novo Nordisk INC $46.19 2023-2025 Wegovy, Ozempic
Abbott Laboratories $44.32 2025 Diamondback Coronary, Xience Skypoint
Boston Scientific Corporation $38.73 2023-2025 Avvigo Guidance System
Edwards Lifesciences Corporation $31.47 2022
Astellas Pharma US INC $30.24 2020-2021
Itamar Medical INC $29.69 2022-2023 Watchpatone
Glaxosmithkline, LLC. $24.31 2023 Trelegy Ellipta
Bridgebio Pharma, INC. $18.11 2025 Attruby
Medtronic Vascular, INC. $16.33 2019
Cook Medical LLC $15.95 2024 Cook
Esperion Therapeutics, INC. $15.94 2022
Scpharmaceuticals INC. $14.23 2024
Lexicon Pharmaceuticals, INC. $14.06 2023 Inpefa
Akcea Therapeutics, INC. $13.54 2019
Arbor Pharmaceuticals, INC. $11.45 2019

4 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$1,397.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

William Smith

$7,685.07

in general payments reported 2019-2025

Years
2019-2025
Top company
Eli Lilly and Company
Context
The $1,523 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/391385/william-smith

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.